Report cover image

Antiepileptic Drug Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Publisher Fortune Business Insights Pvt. Ltd.
Published May 01, 2024
Length 112 Pages
SKU # FOB18820040

Description

Antiepileptic Drug Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032



Growth Factors of Antiepileptic Drug (AED) Market

The antiepileptic drug (AED) market size was valued at USD 16.50 billion in 2023, and the market is now projected to grow from USD 17.13 billion in 2024 to USD 24.85 billion by 2032, exhibiting a CAGR of 4.8% during the forecast period of 2024-2032.

The COVID-19 pandemic negatively affected the global market due to a decline in the name for neurological tablets and offerings and issues with get admission to care. From 2022 onward, the quantity of affected person visits to neurological centers extended.Consequently, the market is expected to go lower again to its pre-pandemic boom fee from 2024 to 2032.

Despite the supply of AEDs within the marketplace, one-third of the population faces drug intolerability. Manufacturers are making efforts to cope with this issue by using developing goal-specific capsules primarily based on the neurobiology of epilepsy. The developing occurrence of epilepsy and the call for effective medicines strain market players to introduce new AEDs, with essential choices via the U.S. FDA encouraging R&D and reaping rewards sufferers.

The want to revisit widespread AED discovery and improvement is crucial to address unmet treatment desires. The patent expiration of 2d-technology capsules affords opportunities for pharmaceutical corporations to develop widely wide-spread and modern capsules. Key game enthusiasts are receiving approvals and launching 1/3-generation pills, boosting marketplace growth and inspiring funding in complicated clinical trials.

Comprehensive Analysis of Antiepileptic Drug (AED)Market

The antiepileptic drug (AED) market growth is rising at an exponential rate due to its market segmentation. This market expansion effectively provides detailed regional assessments considering the dominant supply and demand forces that impact the industry. These segmentations are methodically segregated by drug generation analysis and by distribution channel analysis. By drug generation analysis includes first generation, second generation, and third generation. By distribution channel analysis include, hospital pharmacies, retail pharmacies, and online pharmacies.

The North America region lead the antiepileptic drug (AED) market share by benefitting a market size of USD 7.97 billion in 2023 due the market in the region is characterized by higher diagnosis and treatment rates for neurology conditions.

The top players in the market play a crucial role in the industry assuring market growth and setting market standards. These players include Pfizer Inc. (U.S.), UCB S.A. (Belgium), GSK plc. (U.K.), H. Lundbeck A/S (Denmark), Eisai Co., Ltd. (Japan), Sanofi (France), Sunovion Pharmaceuticals Inc. (U.S.), Jazz Pharmaceuticals, Inc. (Ireland), these market players provide a level-playing competitive landscape.

In December 2022, Eisai Co., Ltd. Agreed to switch the U.S. Commercial rights for the antiepileptic drug (AED) Fycompa to Catalyst Pharmaceuticals, Inc., which turned into also granted an one of a kind negotiation length for an asset in Eisai’s epilepsy pipeline.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2032

Base Year 2023

Forecast Period 2024-2032

Historical Period 2019-2022

Growth Rate CAGR of 4.8% from 2024-2032

Unit Value (USD billion)

Segmentation By Drug Generation

First Generation

Second Generation

Third Generation

ByDistribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

By Region

North America (By Drug Generation, By Distribution Channel, and By Country)

- U.S.

- Canada

Europe (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)

- U.K.

- Germany

- France

- Italy

- Spain

- Scandinavia

- Rest of Europe

Asia Pacific (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)

- Japan

- China

- India

- Australia

- Southeast Asia

- Rest of Asia Pacific

Latin America (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)

- Brazil

- Mexico

- Rest of Latin America

Middle East & Africa (By Drug Generation, By Distribution Channel, and By Country/Sub-Region)

- GCC

- South Africa

- Rest of the Middle East & Africa


Please Note: It will take 5-6 business days to complete the report upon order confirmation.

Table of Contents

112 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Key Insights
4.1. Incidence of Colorectal Cancer (2020) - For Key Countries, 2022/2023
4.2. Overview : Colorectal Cancer Screening Programs (Key Countries/ Regions)
4.3. New Product Approvals
4.4. Overview: Public Private Partnerships, Strategies Implemented by Organizations for Colorectal Cancer Screening - Key Countries
4.5. Number of Colorectal Cancer Screening Procedures - For Key Countries, 2022/2023
4.6. Average Prices of the Tests in the Market
4.7. Key Industry Developments (Mergers, Acquisitions, Partnerships)
4.8. Overview : Countries with Overburden of Colonoscopies
4.9. Impact of COVID-19 on the Market
5. Global Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2019-2032
5.1. Market Analysis, Insights and Forecast – By Type
5.1.1. Stool-based
5.1.1.1. Fecal Immunochemical Test (FIT)
5.1.1.2. Fecal Occult Blood Test (FOBT)
5.1.1.3. Stool-DNA Test
5.1.2. Colonoscopy
5.1.3. Others
5.2. Market Analysis, Insights and Forecast – By End-user
5.2.1. Hospitals & Clinics
5.2.2. Clinical Laboratories
5.2.3. Diagnostic Imaging Centers
5.2.4. Others
5.3. Market Analysis, Insights and Forecast – By Region
5.3.1. North America
5.3.2. Europe
5.3.3. Asia Pacific
5.3.4. Latin America
5.3.5. Middle East & Africa
6. North America Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2019-2032
6.1. Market Analysis, Insights and Forecast – By Type
6.1.1. Stool-based
6.1.1.1. Fecal Immunochemical Test (FIT)
6.1.1.2. Fecal Occult Blood Test (FOBT)
6.1.1.3. Stool-DNA Test
6.1.2. Colonoscopy
6.1.3. Others
6.2. Market Analysis, Insights and Forecast – By End-user
6.2.1. Hospitals & Clinics
6.2.2. Clinical Laboratories
6.2.3. Diagnostic Imaging Centers
6.2.4. Others
6.3. Market Analysis – By Country
6.3.1. U.S.
6.3.2. Canada
7. Europe Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2019-2032
7.1. Market Analysis, Insights and Forecast – By Type
7.1.1. Stool-based
7.1.1.1. Fecal Immunochemical Test (FIT)
7.1.1.2. Fecal Occult Blood Test (FOBT)
7.1.1.3. Stool-DNA Test
7.1.2. Colonoscopy
7.1.3. Others
7.2. Market Analysis, Insights and Forecast – By End-user
7.2.1. Hospitals & Clinics
7.2.2. Clinical Laboratories
7.2.3. Diagnostic Imaging Centers
7.2.4. Others
7.3. Market Analysis – By Country/Sub-region
7.3.1. U.K.
7.3.2. Germany
7.3.3. France
7.3.4. Spain
7.3.5. Italy
7.3.6. Scandinavia
7.3.7. Rest of Europe
8. Asia pacific Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2019-2032
8.1. Market Analysis, Insights and Forecast – By Type
8.1.1. Stool-based
8.1.1.1. Fecal Immunochemical Test (FIT)
8.1.1.2. Fecal Occult Blood Test (FOBT)
8.1.1.3. Stool-DNA Test
8.1.2. Colonoscopy
8.1.3. Others
8.2. Market Analysis, Insights and Forecast – By End-user
8.2.1. Hospitals & Clinics
8.2.2. Clinical Laboratories
8.2.3. Diagnostic Imaging Centers
8.2.4. Others
8.3. Market Analysis – By Country/Sub-region
8.3.1. China
8.3.2. India
8.3.3. Japan
8.3.4. Australia
8.3.5. Southeast Asia
8.3.6. Rest of Asia Pacific
9. Latin America Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2019-2032
9.1. Market Analysis, Insights and Forecast – By Type
9.1.1. Stool-based
9.1.1.1. Fecal Immunochemical Test (FIT)
9.1.1.2. Fecal Occult Blood Test (FOBT)
9.1.1.3. Stool-DNA Test
9.1.2. Colonoscopy
9.1.3. Others
9.2. Market Analysis, Insights and Forecast – By End-user
9.2.1. Hospitals & Clinics
9.2.2. Clinical Laboratories
9.2.3. Diagnostic Imaging Centers
9.2.4. Others
9.3. Market Analysis – By Country/Sub-region
9.3.1. Brazil
9.3.2. Mexico
9.3.3. Rest of Latin America
10. Middle East & Africa Colorectal Cancer Screening Market Analysis, Insights and Forecast, 2019-2032
10.1. Market Analysis, Insights and Forecast – By Type
10.1.1. Stool-based
10.1.1.1. Fecal Immunochemical Test (FIT)
10.1.1.2. Fecal Occult Blood Test (FOBT)
10.1.1.3. Stool-DNA Test
10.1.2. Colonoscopy
10.1.3. Others
10.2. Market Analysis, Insights and Forecast – By End-user
10.2.1. Hospitals & Clinics
10.2.2. Clinical Laboratories
10.2.3. Diagnostic Imaging Centers
10.2.4. Others
10.3. Market Analysis – By Country/Sub-region
10.3.1. GCC
10.3.2. South Africa
10.3.3. Rest of Middle East & Africa
11. Competitive Analysis
11.1. Company Share Analysis for Stool-based Tests, 2023
11.2. Company Share Analysis for Colonoscopes, 2023
11.3. Company Profiles
11.3.1. NOVIGENIX SA
11.3.1.1. Overview
11.3.1.2. Products & Services
11.3.1.3. SWOT Analysis
11.3.1.4. Recent Developments
11.3.1.5. Strategies
11.3.1.6. Financials (Based on Availability)
11.3.2. EIKEN CHEMICAL CO., LTD.
11.3.2.1. Overview
11.3.2.2. Products & Services
11.3.2.3. SWOT Analysis
11.3.2.4. Recent Developments
11.3.2.5. Strategies
11.3.2.6. Financials (Based on Availability)
11.3.3. Clinical Genomics Technologies Pty Ltd.
11.3.3.1. Overview
11.3.3.2. Products & Services
11.3.3.3. SWOT Analysis
11.3.3.4. Recent Developments
11.3.3.5. Strategies
11.3.3.6. Financials (Based on Availability)
11.3.4. Exact Sciences Corporation
11.3.4.1. Overview
11.3.4.2. Products & Services
11.3.4.3. SWOT Analysis
11.3.4.4. Recent Developments
11.3.4.5. Strategies
11.3.4.6. Financials (Based on Availability)
11.3.5. Epigenomics AG
11.3.5.1. Overview
11.3.5.2. Products & Services
11.3.5.3. SWOT Analysis
11.3.5.4. Recent Developments
11.3.5.5. Strategies
11.3.5.6. Financials (Based on Availability)
11.3.6. bioMérieux, Inc.
11.3.6.1. Overview
11.3.6.2. Products & Services
11.3.6.3. SWOT Analysis
11.3.6.4. Recent Developments
11.3.6.5. Strategies
11.3.6.6. Financials (Based on Availability)
11.3.7. OLYMPUS CORPORATION
11.3.7.1. Overview
11.3.7.2. Products & Services
11.3.7.3. SWOT Analysis
11.3.7.4. Recent Developments
11.3.7.5. Strategies
11.3.7.6. Financials (Based on Availability)
11.3.8. KARL STORZ SE & Co. KG
11.3.8.1. Overview
11.3.8.2. Products & Services
11.3.8.3. SWOT Analysis
11.3.8.4. Recent Developments
11.3.8.5. Strategies
11.3.8.6. Financials (Based on Availability)
11.3.9. FUJIFILM Holdings America Corporation
11.3.9.1. Overview
11.3.9.2. Products & Services
11.3.9.3. SWOT Analysis
11.3.9.4. Recent Developments
11.3.9.5. Strategies
11.3.9.6. Financials (Based on Availability)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us